<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20040929085129+02'00'</creation_date><modification_date>D:20040929085129+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-04-285_h_dec_0.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 27-ix-2004 c(2004)3653 
 not for publication</p></section><section><header>commission decision of 27-ix-2004 
 granting marketing authorisation for the medicinal product for human use &quot;apidra 
 - insulin glulisine&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>only the german text is authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 27-ix-2004 
 granting marketing authorisation for the medicinal product for human use &quot;apidra 
 - insulin glulisine&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and in particular article 10(2) thereof, 
 having regard to the application submitted by aventis pharma deutschland gmbh, on 
 23 june 2003, under article 4(1) of regulation (eec) no 2309/93, 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 3 june 2004, 
 whereas: 
 (1)</p><p>the medicinal product &quot;apidra - insulin glulisine&quot; complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of 
 the council of 6 november 2001 on the community code relating to medicinal 
 products for human use
 3 as amended by directive 2002/98/ec4 and by directive 2003/63/ec
 5. (2)</p><p>it is therefore appropriate to authorise its placing on the market. 
 (3)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 1 oj l 214, 24. 8. 1993, p. 1. 2 oj l 88, 24.3.1998, p. 7. 3 oj l 311, 28.11.2001, p. 67. 4 oj l 33, 8.2.2003, p. 30. 5 oj l 159, 27.6.2003, p. 46.</p></section><section><header>en  
   en</header><p>has adopted this decision: article 1 the marketing authorization referred to in article 3 of regulation (eec) no 2309/93 is hereby granted in respect of the medicinal product, &quot;apidra - insulin glulisine&quot; whose 
 characteristics are summarized in annex i hereto. this medicinal product shall be entered 
 in the community register of medicinal products under the numbers: 
 eu/1/04/285/001 
 apidra-100 u/ml-solution for injection-subcutaneous use-vial 
 (glass)-10 ml -1 vial 
 eu/1/04/285/002 
 apidra-100 u/ml-solution for injection-subcutaneous use-vial 
 (glass)-10 ml - 2 vials 
 eu/1/04/285/003 
 apidra-100 u/ml-solution for injection-subcutaneous use-vial 
 (glass)-10 ml -4 vials 
 eu/1/04/285/004 
 apidra-100 u/ml-solution for injection-subcutaneous use-vial 
 (glass)-10 ml - 5 vials 
 eu/1/04/285/005 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -1 cartridge 
 eu/1/04/285/006 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -3 cartridge 
 eu/1/04/285/007 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -4 cartridges 
 eu/1/04/285/008 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -5 cartridges 
 eu/1/04/285/009 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -6 cartridges 
 eu/1/04/285/010 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -8 cartridges 
 eu/1/04/285/011 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -9 cartridges 
 eu/1/04/285/012 
 apidra-100 u/ml-solution for injection-subcutaneous use-cartridge 
 (glass)-3 ml -10 cartridges 
 eu/1/04/285/013 
 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -1 pre-filled pen 
 eu/1/04/285/014 
 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -3 pre-filled pens</p></section><section><header>en  
   en</header><p>eu/1/04/285/015 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -4 pre-filled pens 
 eu/1/04/285/016 
 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -5 pre-filled pens 
 eu/1/04/285/017 
 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -6 pre-filled pens 
 eu/1/04/285/018 
 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -8 pre-filled pens 
 eu/1/04/285/019 
 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -9 pre-filled pens 
 eu/1/04/285/020 
 apidra -100 u/ml-solution for injection-subcutaneous use-pre-filled 
 pen (glass) (optiset)-3 ml -10 pre-filled pens 
 article 2 the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and importation, control and issue referred to in annex ii. 
 article 3 the labelling and package leaflet concerning the medicinal product referred to in article 1 shall conform to annex iii. 
 article 4 the period of validity of the authorization issued shall be five years from the date of notification of this decision. it shall be renewable under the conditions laid down in 
 article 13(1) of regulation (eec) no 2309/93. 
 article 5 this decision is addressed to aventis pharma deutschland gmbh, brueningstrasse 50, d-65926 frankfurt am main, deutschland. 
 done at brussels, 27-ix-2004 
 for the commission olli rehn 
 member of the commission</p></section></body></xml>